Publication | Closed Access

The Xc− inhibitor sulfasalazine improves the anti-cancer effect of pharmacological vitamin C in prostate cancer cells via a glutathione-dependent mechanism

Medicinal ChemistryXc− Inhibitor SulfasalazineOncologyMedicineGlutathione-dependent MechanismCancer Cell BiologyProstate Cancer CellsPharmacotherapyAnti-cancer AgentCancer TreatmentProstatic DiseasePharmacologyRadiation Oncology